Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Proactive Video: Todos Provista lab's new automation sees significant increase in COVID-19 PCR testing volume
11/2/21 - 6 minutes in length. More detailed info to supplement the press release today.
Adding another 500K shares between today and tomorrow. This is going higher. Much higher.
I also added more shares today. Plan to continue buying through end of year.
Todos Medical Announces 2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
§ Interim Clinical Trial Data from Phase 2 expected in Q4/21
§ Nature Neuroscience and Cell Reports publications highlight 3CLpro (Mpro)’s complementary mechanisms of virus replication and immune suppression
New York, NY, and Tel Aviv, ISRAEL, Nov. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and theranostic solutions company, today announced it is now adding the Hillel Yaffe Medical Center as the 2nd clinical trial site in Hadera, Israel for its ongoing Tollovir® Phase 2 randomized, double blind, placebo controlled clinical trial for the treatment of hospitalized COVID-19 patients. Tollovir is an oral 3CL Protease (3CLpro, Main Protease, MPro, Nsp5) antiviral/anti-cytokine therapeutic candidate focused on blocking the 3CL Protease. The Shaare Zedek Medical Center in Jerusalem, Israel was the first site opened in April 2021 having enrolled 30 patients to date. An independent review of interim safety and efficacy data by the Data Safety Monitoring Board (DSMB) of the randomized trial data collected is expected in Q4/2021 that will guide the next steps in the program’s development path towards the therapeutic treatment of COVID-19.
“We believe the addition of a 2nd clinical trial site will accelerate enrollment in our ongoing Phase 2 randomized trial and also expand Tollovir’s clinical footprint,” said Gerald Commissiong, President & CEO of Todos Medical. “The upcoming data analysis is quite significant as it will guide the next steps in our clinical development pathway as we look at the potential use of Tollovir beyond hospitalized patients and potentially evaluating its efficacy in Moderate COVID (pre-hospital) and Long COVID in the future.”
“The recent functional validation of our 3CLpro long ongoing research by two independent groups with publications on 3CLpro in Nature Neuroscience and Cell Reports really provides strong support for the clinical outcomes we have seen in Israel since the pandemic began,” said Dr. Dorit Arad, Chief Scientific Officer of NLC Pharma, the Company’s 3CL protease therapeutic and diagnostics joint venture partner. “We are now evaluating the clinical development implications of these findings on our upcoming Tollovir Phase 2 interim analysis, as well as proposed programs in Moderate COVID and Long Haul trial, as well as looking at pediatric populations who have very few options at the moment. Given that Tollovir is well tolerated, we see the potential to help children suffering from COVID-19.”
https://investor.todosmedical.com/news-events/press-releases/detail/146/todos-medical-announces-2nd-clinical-trial-site-for
I was not an investor in Amarantus, so my perspective is obviously somewhat different that those who lost money, or are still holding shares with large paper losses, waiting for the phoenix to rise from the ashes, which may be possible with a new CEO and proper funding. I believe a number of their assets such as MANF and ESS have great potential if properly funded and moved forward.
From my perspective of not having personally experienced the Amarantus decline, but having spent many hours reading through years of Amarantus postings and press releases, it appears to me Gerald worked to implement his business plan of acquiring undervalued assets and de-risking them by putting them through the required lab and clinical testing, but acquired more assets than he had the ability to manage given there was no revenue and funding was not on terms beneficial to shareholders.
It's like playing Monopoly and trying to buy every property you land on, even when you don't have the cash, and you mortgage existing assets to fund these purchases, thinking you'll eventually generate revenue from them. You can overextend yourself and end up bankrupt. Sometimes you have to let that great property go to another player because you can't afford it, and not being able to recognize that is the mark of an inexperienced player. Essentially that's what Gerald was with Amarantus. Very polished speaker and very knowledgeable of the assets and their potential, but acquired more assets than were manageable with limited resources and ultimately tanked the company, putting them in a holding status at a sub-penny share price. I believe his Stanford degree with a "focus on financial engineering" made him overconfident in a penny stock world where he had little to no experience, and he made some bad decisions as a result. I do hope that phoenix can rise from the ashes and reward those still holding shares.
One of the common traits of many successful people is they have pasts littered with failures, sometimes big ones. Failures can be the best teacher in life. I can only hope that Gerald has learned from his failures at Amarantus and make better decisions at Todos Medical. I believe I have seen some indications of that here, but ultimately the only way we'll know will depend on the level of success that is achieved. The Tollovir preliminary data and reports certainly look like great success is close. That's one reason some of us are increasing our share positions, and some new investors are joining IHUB and posting having made their first purchase. Hope that continues.
I understand the anger and frustration some have from their Amarantus experience. I understand how some blame the CEO for their losses. Personally, I blame the person I see in the mirror if I make a bad investment decision, but that's how I roll. Some even make it their mission to bash and discredit the CEO at every opportunity, even on the Todos board where they have no investment. What I don't understand is those who believe Gerald lied or deceived them at Amarantus, yet are invested in Todos with Gerald at the helm. I would not be investing with anyone I believe lied to me or intentionally deceived me. No way, never again. Again, that's how I roll.
So that's my perspective on our CEO's past. I've been posting here for a year or so. I started here with a small investment, and have added to it as things have unfolded in ways I interpret as favorable. I'm not pleased with everything that's happened, but I'm also able to look at the bigger picture and not be overly critical on every little detail. There's much going on behind the scenes with Todos that we have no idea about. There's more folks working to make this a success than just the CEO. I believe these are good people working very hard to be successful as a company. That's why I invested more and will continue to invest prior to the Phase 2 Tollovir data release. I understand the risks and I will accept responsibility for the outcome, not blame the CEO. Exciting times ahead. GLTA
I usually get a reply to my Twitter questions to Gerald, but not always. Here's a couple of recent inquiries where I didn't get a reply. I'm still holding out for a reply to the last question, as I have posted questions to both Investor Relations and to the CFO for clarification on some of the filings, with no reply and not even an acknowledgement they received my inquiry. I can understand if they can't provide the details I'm asking about, but they should at least be responding to shareholders. So I address the question to Gerald after seeing his closing statement in the Benzinga presentation where he encouraged questions to be directed to the company via the web site. Maybe my question will result in some internal inquiries by the CEO to fix this issue. Others here have posted their questions went unanswered as well. That's gotta change.
Added more Todos shares today. Buying more on Monday. I weighed the risk and potential rewards based on the news, presentations, and not-so-impressive results from competitors products, and made the decision to invest more here. If Tollovir is as effective as all preliminary indicators are suggesting, this could have a profound impact on the virus, unmatched by any competitor. Shareholders could be rewarded extremely well.
I promise I won't blame the CEO if this investment doesn't work out. I'm not betting the farm on this, and the guy in the mirror is the one who holds responsibility for my choices.
GLTA
I added more today as well, and will pick up another chunk of shares within the next two weeks.
I see some new investors here. Not unexpected with the number of presentations being done and news starting to get out about the potential game-changer with Tollovir/Tollovid. Some are determining it's worth the risk with potentially enormous rewards. Imagine in a couple of months the positive data and news driving this to $1-$2 price range... minimal RS would get us uplisted to Nasdaq. Seems reasonable given the market potential for their Covid treatment just published.
GLTA who invested and to those who held their shares through all the fear and negativity posted here over the last year. We are getting close to seeing our investment potential realized.
Bought more Todos Medical shares today, and will pick up more later in the week as new money rolls into my accounts.
Exciting times ahead for Todos investors.
Todos Medical Announces Publication in Nature Neuroscience That Describes the Main Protease (3CL Protease) Causes Microvascular Brain Pathology
https://investor.todosmedical.com/news-events/press-releases/detail/144/todos-medical-announces-publication-in-nature-neuroscience
New York, NY, and Tel Aviv, ISRAEL, Oct. 25, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced the publication of an article entitled “The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells” in the peer-reviewed scientific journal Nature Neuroscience (https://www.nature.com/articles/s41593-021-00926-1) by researchers at the University of Lübeck in Germany. The article describes the mechanisms through which the main protease (Mpro, Nsp5, 3CL protease, 3CLpro or 3CLpro) cleaves the nuclear factor (NF)-?B essential modulator (NEMO) which is involved in signaling cascades that regulate the transcription of numerous genes, including the antiviral type I interferons and other immune genes. The publication concludes that “Mpro-mediated damage of the brain endothelial cells suggests that inhibitors of Mpro may prevent neurological complications of the SARS-CoV-2 infection.”
Todos Medical, together with its joint venture partner NLC Pharma, is developing Tollovir®, an Mpro (3CL protease) inhibitor currently in a Phase 2 clinical trial for treatment of hospitalized COVID-19 patients with interim data expected from the trial in the fourth quarter of 2021.
“We have long known the importance of Mpro in facilitating the replications and spread of COVID-19,” said Dr. Dorit Arad, Chief Scientific Officer of NLC Pharma. “What we are now beginning to understand is how Mpro not only facilitates viral replication, but also how it impacts the body’s ability to respond to the virus. Based on this publication, and additional work we’ve been doing to further elucidate the mechanisms through which Mpro facilitates the spread of SARS-CoV-2 and magnifies the damage the virus can cause in the body, we believe inhibitors of Mpro are ideal drug targets. This gives us great confidence in Tollovir’s potential in treating COVID-19 at all stages of disease, from prevention through hospitalization. We are currently focused on hospitalization, where the fewest treatment options exist, however we are continuing to evaluate outpatient trial designs to further expand the potential of Tollovir to help patient afflicted with COVID-19. With this publication related to neuroscience, we see the tip of the iceberg of how Mpro can damage parts of the immune system. We are quite certain that our yet to be published recent discoveries regarding Mpro’s additional function will revolutionize the way COVID, and potentially post-acute long-haul symptoms, are treated.”
Share Structure Update - 10/22/21
https://www.otcmarkets.com/stock/TOMDF/security
Well stated. I wish more investors understood that small companies in this position have difficulty finding financing at attractive or what some would even consider reasonable terms. The company is to some degree over a barrel and the financiers know this, which is why they structure the deal more heavily to their favor. It's not like there's a line of financiers standing by with better terms the company can easily turn to.
Perhaps some wouldn't be so unhappy with their investment here with every new financing deal that is announced, but realize it's a reality in the OTC penny stock world they've elected to invest in. It's far different than terms of a traditional business loan a profitable, established company.
There's a high risk to lose one's investment, offset by much higher potential gains if the company succeeds. Most of a person's investments should be in higher quality equities and only the smaller portion they can afford to lose invested here. Unfortunately, I suspect many investing here are taking on much more risk than they're comfortable with because not enough effort was made early enough into the higher quality equities and now they're looking for a Hail Mary pass with this investment to change their reality. And I also suspect some of those who continuously attack this CEO because they lost a lot of money in AMBS were in the same boat, and possibly still are, which is what fuels their continued anger here, lashing out at a CEO who they once saw as their financial savior, and now blame him when those fortunes failed to materialize.
Not preaching... just an observation I suspect is more accurate than most will admit.
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
Company hosting cPass webinar on Friday, October 22, 2021 for long-term care facilitiesNew York, NY, and Tel Aviv, ISRAEL, Oct. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced the publication of an article entitled “A Practical Approach to SARS-CoV-2 Testing in Pre and Post Vaccination Era” in the peer-reviewed Journal of Clinical Virology, available online at https://www.sciencedirect.com/science/article/pii/S2667038021000363?via%3Dihub , that highlights the clinical utility of combining the cPass neutralizing antibody test in the vaccinated and COVID-recovered populations with PCR testing in the unvaccinated and not previously infected to reduce COVID-19 transmission. Todos Medical is hosting a webinar entitled “New Paradigm for Measuring Immunity in Pre- and Post-Vaccination Era” on Friday, October 22nd, 2021 at 12:00pm ET for The Society for Post-Acute and Long-Term Care Medicine (“AMDA”), and is available for anyone to attend virtually on Todos’ YouTube Channel at: https://www.youtube.com/channel/UCWsJLl1iB9qlZUSicQ9e-Mg.
The publication concluded, “To minimize the potential for future outbreaks, a revised testing strategy to assure initial and continued protection post-vaccination will likely be required. This could include a combination of qPCR (for non-vaccinated and susceptible people) and nAb (for previously infected and vaccinated people) assays. cPass sVNT could be a useful tool for substantiating individual immunity in a SARS-CoV-2 post-vaccination era.”
Provista Dx offers high-throughput SARS-CoV-2 PCR testing and high-throughput semi-quantitative cPass neutralizing antibody testing as services. For more information on Provista’s testing services, please contact James Doherty, Sr. Director of Business Development at Provista Diagnostics at dohertyj@provistadx.com.
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
https://investor.todosmedical.com/news-events/press-releases/detail/143/todos-medical-announces-publication-in-journal-of-clinical
From page 9 of the Q2 10-Q:
Going Concern Uncertainty
Until 2020, we devoted substantially all of our efforts to research and development and raising capital. In 2020, we raised significant capital, but we also generated revenues for the first time as a result of our activities related to Covid-19. There is no certainty as to the continuance of our revenues related to Covid-19. The development and commercialization of our other products, which are necessary for our long term financial health, are expected to require substantial further expenditures. We remain dependent upon external sources for financing our operations. Since inception, we have incurred substantial accumulated losses, negative working capital, and negative operating cash flow, and have a significant shareholders’ deficit. These factors raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. We plan to finance our operations through the sale of equity and, to the extent available, short term and long-term loans. There can be no assurance that we will succeed in obtaining the necessary financing to continue our operations.
Regarding the missing sales you keep bringing up, the following statements appear in the Q2 2021 SEC filing. I believe GC also commented on this in a tweet a while back, but I'm not inclined to dig through those. Hopefully the company will collect the unpaid sales revenue from the customer without having to go to court.
From page F-23, Major Customers:
During the year ended December 31, 2020, the Company had one costumer which represents 56.64% of the Company’s total sales. During the Six months ended June 30, 2021, the Company had one costumer which represents 63.43% of the Company’s total sales with which Company’s contractual agreement to supply Covid-19 testing kits to a significant customer expired.
The increase in our revenues is a result of the sales of our COVID-19 testing products through our U.S. subsidiary, Corona Diagnostics, LLC. Revenues for the six and three months ended June 30, 2021 include $4,290,000 of revenues to our significant customer with which Company’s contractual agreement to supply Covid-19 testing kits to a significant customer expired – see Recent Development below
During the first quarter of 2021, the Company’s contractual agreement to supply Covid-19 testing kits to a significant customer expired. At the customer’s request, the Company continued to supply Covid-19 testing kits until such time as the customer requested that the Company stop doing so. The customer has not yet paid for some of the Covid-19 testing kits so supplied, and has not yet renewed its agreement with the Company. The Company believes that ultimately the customer will pay for the Covid-19 testing kits so supplied and will renew its agreement to purchase Covid-19 testing kits from the Company. Should the customer not renew its agreement to purchase Covid-19 testing kits from the Company, it could have a material adverse effect on the Company’s revenues from the sale of Covid-19 testing kits.
I don't know why the company doesn't respond to emails. I have used the means where I have seen others getting responses... Twitter. I signed up for the free account solely to use to communicate with the CEO. Perhaps you could give that a try and have better success.
What's up with the huge volume in AMBS around 3:30 p.m.? Someone catch a rumor of something?
Maybe someone had another "Come to Jesus" talk with the CEO and convinced some "whales" to buy shares. Happened before I heard.... kinda. The talk and the phone calls happened, but not much buying because everyone knew the guy was only interested in conning shareholders to support whatever side of the swing trade he was currently on. Some wannabe investment analyst. Sad, but true. I guess you encounter all types on these boards.
Maybe this time it was different and some whales actually did buy AMBS shares and created enough demand to drive the price 22% higher in the last 30 minutes of the day. The late volume was not typical for this stock.
Your Tollovid question is answered in Gerald's reply to my Twitter question. Scroll down to middle of the post.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166427511
Thanks for the opinion. Could have just advised against investing in penny stocks altogether.